ERBB2 and cancer: Indeed, a recent phase II study of combination trastuzumab plus lapatinib in KRAS wt and HER2 IHC 2/3+ and FISH + cancers met its primary efficacy endpoint and reported a 32% response rate in patients with advanced, treatment refractory cancer [36].